MINI FUTURE LONG - ZEALAND PHARMA | Delayed Börse Stuttgart 11:39:46 06/06/2024 BST | ||
| 2.61 EUR | +18.64% |
|
| Current month | -11.29% | ||
| 1 month | -6.78% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 06/06/24 | 2.61 | +18.64% |
| 05/06/24 | 2.2 | +3.77% |
| 04/06/24 | 2.12 | -20.90% |
| 03/06/24 | 2.68 | +8.06% |
| 31/05/24 | 2.48 | +10.71% |
Delayed Quote Börse Stuttgart
Last update June 06, 2024 at 11:39 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MG253T |
| ISIN | DE000MG253T4 |
| Date issued | 11/04/2024 |
| Strike | 448.6 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.33 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.99 € |
|---|---|
| Lowest since issue | 1.77 € |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
610.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+28.68%
- Stock Market
- Certificates
- Certificat
